Boralex Inc.
Boralex Inc. (BLX.TO) Financial Performance & Income Statement Overview
Analyze Boralex Inc. (BLX.TO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Boralex Inc. (BLX.TO) Income Statement & Financial Overview
Review Boralex Inc. BLX.TO income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $226.00M | $237.00M | $159.00M | $189.00M |
| Cost of Revenue | $0.00 | $118.00M | $45.00M | $40.00M |
| Gross Profit | $226.00M | $119.00M | $114.00M | $149.00M |
| Gross Profit Ratio | $1.00 | $0.50 | $0.72 | $0.79 |
| R&D Expenses | $11.00M | $16.00M | $16.00M | $13.00M |
| SG&A Expenses | $18.00M | $17.00M | $19.00M | $21.00M |
| Operating Expenses | $161.00M | $33.00M | $107.00M | $34.00M |
| Total Costs & Expenses | $161.00M | $159.00M | $152.00M | $154.00M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $35.00M | $34.00M | $29.00M | $30.00M |
| Depreciation & Amortization | $80.00M | $68.00M | $77.00M | $74.00M |
| EBITDA | $171.00M | $118.00M | $93.00M | $112.00M |
| EBITDA Ratio | $0.76 | $0.50 | $0.58 | $0.59 |
| Operating Income | $65.00M | $78.00M | $7.00M | $35.00M |
| Operating Income Ratio | $0.29 | $0.33 | $0.04 | $0.19 |
| Other Income/Expenses (Net) | -$9.00M | -$72.00M | -$20.00M | -$15.00M |
| Income Before Tax | $56.00M | $6.00M | -$13.00M | $20.00M |
| Income Before Tax Ratio | $0.25 | $0.03 | -$0.08 | $0.11 |
| Income Tax Expense | $15.00M | $8.00M | $1.00M | $3.00M |
| Net Income | $30.00M | -$16.00M | -$14.00M | $11.00M |
| Net Income Ratio | $0.13 | -$0.07 | -$0.09 | $0.06 |
| EPS | $0.29 | -$0.16 | -$0.14 | $0.11 |
| Diluted EPS | $0.29 | -$0.16 | -$0.14 | $0.11 |
| Weighted Avg Shares Outstanding | $102.77M | $102.77M | $102.77M | $102.77M |
| Weighted Avg Shares Outstanding (Diluted) | $102.80M | $102.77M | $102.77M | $102.81M |
Over the past four quarters, Boralex Inc. demonstrated steady revenue growth, increasing from $189.00M in Q2 2024 to $226.00M in Q1 2025. Operating income reached $65.00M in Q1 2025, maintaining a consistent 29% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $171.00M, reflecting operational efficiency. Net income rose to $30.00M, with EPS at $0.29. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan